Mitiglinide calcium hydrate is an oral medication used in the treatment of type 2 diabetes. It is a chemical compound with the chemical name (S)-(+)-2-((P-(2-(Ethoxy)Ethyl)benzenesulfonyl)Amino)-3-cyclohexylpropionic acid calcium hydrate and has the molecular formula C19H30CaN2O5S. Its formula weight is 456.64 g/mol, and its CAS number is 145525-41-3.
Top ten keywords from Google regarding Mitiglinide calcium hydrate are:
Synonyms for Mitiglinide calcium hydrate include KAD-1229, AY-4166, and Glufast.
Health benefits of Mitiglinide calcium hydrate:
Mitiglinide calcium hydrate is primarily used in the treatment of type 2 diabetes to manage blood glucose levels. Similar to Nateglinide, it stimulates insulin secretion from pancreatic beta cells in response to food intake, thus lowering postprandial hyperglycemia. As a result, it can help improve glycemic control in patients with type 2 diabetes.
Potential effects of Mitiglinide calcium hydrate:
The primary effect of Mitiglinide calcium hydrate is stimulation of insulin secretion from pancreatic beta cells. This leads to lower blood glucose levels after meals, particularly in patients with type 2 diabetes who exhibit impaired insulin secretion. Additionally, Mitiglinide calcium hydrate has been shown to have a rapid onset of action, allowing for more precise control of postprandial hyperglycemia.
Product mechanism:
The mechanism of action of Mitiglinide calcium hydrate involves stimulation of insulin secretion from pancreatic beta cells via inhibition of ATP-sensitive potassium channels. This results in an increase in intracellular calcium concentration, which leads to exocytosis of insulin-containing granules.
Safety:
Mitiglinide calcium hydrate has been tested in preclinical studies and clinical trials, and its safety profile has been well-established. However, like any other drug, there may be some side effects associated with its use. Therefore, it is important to consult a physician before taking this drug.
Side effects:
Some of the common side effects associated with the use of Mitiglinide calcium hydrate include headache, dizziness, nausea, and hypoglycemia. In rare cases, more serious side effects such as liver toxicity have been reported.
Dosing information:
The dosing of Mitiglinide calcium hydrate varies depending on the individual patient and their response to treatment. Therefore, it is important to follow the dosage instructions provided by a healthcare professional. Mitiglinide calcium hydrate is typically taken orally before meals.
Conclusion:
Mitiglinide calcium hydrate is a useful medication for the management of blood glucose levels in patients with type 2 diabetes. As an insulin secretagogue, it can stimulate insulin secretion from pancreatic beta cells and lower postprandial hyperglycemia. While its safety profile has been established, it is important to consult with a healthcare professional before taking this drug
